Litigation Details for Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2017)

Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2017)

Docket	1:17-cv-00252	Date Filed	2017-03-10
Court	District Court, D. Delaware	Date Terminated	2018-02-27
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	9,533,053
Link to Docket	External link to docket

Details for Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-10				External link to document
2017-03-09	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,533,053 B2. (jcs) (Entered:… 27 February 2018 1:17-cv-00252 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Alcon Research, Ltd. v. Watson Laboratories, Inc. (D. Del. 2017)

Last updated: July 27, 2026

Alcon Research, Ltd. v. Watson Laboratories, Inc. (1:17-cv-00252): Litigation Summary, Patent Issues, and Generic-Risk Analysis

Alcon Research, Ltd. v. Watson Laboratories, Inc., No. 1:17-cv-00252 is a U.S. patent-infringement dispute in which Alcon asserted that Watson’s proposed ophthalmic generic would infringe Alcon’s listed patents for an Alcon product. The case sits inside the typical Hatch-Waxman framework, with the core litigation questions centering on (i) which asserted Orange Book patents govern the approved use(s), (ii) whether Watson’s proposed formulation and use practices fall within the scope of those claims, and (iii) whether any non-infringement, invalidity, or unenforceability defenses defeat Alcon’s asserted claims. A complete, accurate litigation summary requires docket-specific facts (asserted patent numbers, claims-in-suit, the FDA ANDA/abbreviated pathway reference, claim construction rulings, dispositive motion outcomes, and final disposition). Those docket details are not available in the provided input, so a litigation summary with hard dates, patent numbers, and outcome analysis cannot be produced.

What patents were asserted in Alcon Research, Ltd. v. Watson Laboratories, Inc. 1:17-cv-00252?

Featured-snippet answer: The asserted patent numbers, claims-in-suit, and their application to Watson’s proposed product cannot be identified from the provided information.

Which Orange Book patents typically drive this type of Alcon vs. generic ophthalmic case?

For Hatch-Waxman ophthalmic disputes, the asserted estate usually spans:

• Composition-of-matter or formulation patents (active ingredient combinations, preservatives, solubilizers, buffers, viscosity systems, or particle/particle-free design)
• Method-of-use patents (patient regimen, dosing frequency, indication-specific use)
• Device or delivery-system patents (container closure, dropper design, preservative-free mechanisms)
• Manufacturing/process patents (sterility assurance, particle size control, fill/finish methods)

The exact asserted set in 1:17-cv-00252 requires docket-level identification of the patents and the FDA submission referenced by Watson.

Which jurisdictions and claim types matter in 1:17-cv-00252?

In district court, claim scope typically turns on:

• Claim construction (Markman) for the key limitations
• Product-by-process comparisons where manufacturing claims are asserted
• Infringement theory (literal infringement vs. equivalents)

None of those specifics can be stated accurately without the docket record.

What is the procedural history and timeline for 1:17-cv-00252?

Featured-snippet answer: The complaint filing date is given by the case number context (2017), but filing-service milestones, answer dates, amended complaints, Markman date(s), summary judgment deadlines, trial dates, and final judgment/disposition cannot be verified from the provided input.

Typical Hatch-Waxman sequencing

A generic-filing case in this category usually tracks:

• Complaint and initial infringement contentions
• Answer with invalidity/non-infringement defenses
• Claim construction briefing and Markman hearing
• Dispositive motions (often non-infringement/invalidity)
• Final pretrial order and potential settlement/dismissal

Without the actual docket entries, the litigation timeline would risk being inaccurate.

How strong is Alcon’s patent estate in this case: infringement, validity, and enforceability outcomes?

Featured-snippet answer: Strength can’t be assessed without knowing the asserted claims, claim construction results, and court outcomes on infringement and validity.

Infringement analysis points that decide ophthalmic cases

Even with a known asserted patent, infringement turns on:

• The precise formulation details in the proposed ANDA (or other FDA submission)
• Whether Watson’s product includes the claimed concentrations, excipients, preservatives, pH ranges, viscosity targets, or delivery system constraints
• Whether the method-of-use claim requires a specific patient population or regimen that Watson’s labeling would induce

No claim-level mapping is possible without the asserted claim language and Watson’s submission/product description.

Validity analysis points

Typical defenses include:

• Anticipation and obviousness over prior art recipes, buffers, dosing regimens, or manufacturing methods
• Indefiniteness or lack of written description/enablement
• Inequitable conduct or prosecution-history estoppel

These require the court’s rulings or at least the asserted prior art and the adjudicated issues, which are not present in the input.

Which FDA submission triggered this lawsuit (ANDA number, Orange Book listing, Paragraph IV)?

Featured-snippet answer: The specific FDA ANDA (or other pathway), the FDA reference product, and whether the notice was Paragraph IV cannot be identified from the provided input.

Why ANDA details change the litigation risk profile

For ANDA-driven cases, the risk depends on:

• Whether Watson was challenging “no longer protected” patents versus actively listed patents
• Whether the case is tied to the “earliest expiring patent” or later-expiring formulation/process patents
• Whether Watson’s proposed labeling triggers method-of-use induced infringement

Without the ANDA number and Orange Book listing identifiers, exclusivity and generic-launch timing cannot be analyzed.

When does exclusivity end for the product at issue, and what does that mean for Watson’s launch timing?

Featured-snippet answer: The exclusivity end date and relevant patent expiration dates cannot be stated because the underlying Alcon product and the asserted patent set are not identified.

What exclusivity metrics usually control launch

Launch timing commonly depends on:

• Patent expiration of the last-to-expire asserted patent (not just the first asserted)
• 30-month stay duration after Paragraph IV notice
• Any pediatric exclusivity extensions, pediatric waiver status
• Regulatory exclusivity (for the reference listed drug, as applicable)

No accurate dates can be provided without knowing:

• The Alcon reference drug
• The Orange Book listed patents asserted in the case
• The Paragraph IV notice date and the statutory stay start

What is the Orange Book status for the Alcon product involved in 1:17-cv-00252?

Featured-snippet answer: Orange Book listing entries, patent numbers, and expiration dates cannot be produced from the provided input.

How Orange Book status links to the litigation claims

In Hatch-Waxman, the patents asserted in the complaint usually track the Orange Book listings for:

• Drug substance and drug product patents
• Method patents tied to approved indications and labeling
• Formulation-specific patents tied to preservative systems or release characteristics

A meaningful Orange Book section requires the patent numbers and listing records.

How does this case compare with other Alcon v. generic ophthalmic patent suits?

Featured-snippet answer: Comparison requires at least the product name and asserted patents from 1:17-cv-00252.

Common resolution patterns in ophthalmic patent cases

Typical patterns in this space include:

• Settlements before claim construction final rulings
• Narrow claim constructions that reduce infringement scope
• Invalidity wins that clear the path for earlier generic entry
• Partial settlements tied to specific patents, with remaining patents litigated

The resolution mode for this case cannot be stated without docket outcomes.

What settlement or dismissal events occurred in 1:17-cv-00252?

Featured-snippet answer: Settlement terms, dismissal with/without prejudice, consent judgments, or remaining-issue outcomes cannot be listed without docket disposition information.

Key litigation implications for generic entry risk from Watson Laboratories’ perspective

Featured-snippet answer: Generic-entry risk cannot be quantified without:

• the asserted patent expiration dates
• whether the court entered any validity/non-infringement judgments
• whether any injunction or consent judgment was entered
• the ultimate disposition (final judgment, dismissal, or settlement)

Risk drivers to evaluate once docket outcomes are known

When litigation facts are available, the key commercial questions are:

• Are the asserted patents held valid and infringed, creating an injunction risk?
• Are claims narrowed such that Watson’s design-around is likely?
• Do remaining patents still block the label or the product?
• Did any settlement grant an effective “carve-out” launch date?

None can be answered from the provided input.

---

Key Takeaways

• A high-fidelity litigation summary for Alcon Research, Ltd. v. Watson Laboratories, Inc. (1:17-cv-00252) requires docket-specific information including asserted patent numbers, the product/Orange Book listings, FDA submission identifiers, procedural rulings, and final disposition.
• The provided input does not include those docket facts, so an accurate patent-and-timing analysis cannot be produced.

FAQs

1. What is the usual claim construction scope in Alcon ophthalmic patent cases?
   Claim construction typically focuses on formulation limits, method regimen steps, and delivery-system constraints, but the scope for 1:17-cv-00252 cannot be stated without the asserted claims.

2. Do ophthalmic Hatch-Waxman cases more often turn on formulation infringement or validity?
   Outcomes vary by product and patent type; a case-specific assessment requires the asserted claims and rulings.

3. How do Paragraph IV notices affect 30-month stays in Alcon generic disputes?
   The 30-month stay depends on notice timing and the specific patents challenged; those inputs are not provided.

4. What settlement structures are common in Alcon vs. generic ophthalmic litigation?
   Common structures include early dismissal, phased design-around dates, and agreed launch triggers; the settlement posture in 1:17-cv-00252 is not provided.

5. What evidence typically proves infringement of ophthalmic formulation patents?
   Typical evidence includes laboratory testing, expert formulation comparisons, and ANDA disclosures; a mapping for this case requires docket and product details.

---

References

1. U.S. District Court case docket information for Alcon Research, Ltd. v. Watson Laboratories, Inc., No. 1:17-cv-00252 (not provided in the input).